Citations

Clear

1320 citation(s) found for "Nguyen, Vi".

Is cytomegalovirus infection related to mycophenolate mofetil after kidney transplantation?1
Munn, Stephen, Payá, Carlos V., Velosa, Jorge A., Nguyen, Justin H. , Sarmiento, Juan M.

Mayo Clinic

Clinical Transplantation | September 30, 2024 | Volume: 12 | Issue: 5 | Pages: 371-374

10.1111/j.1399-0012.1998.tb00983.x Get It

Three multicenter studies have shown that the addition of mycophenolate mofetil (MMF) to an immunosuppressive regime consisting of cyclosporin A (CSA) and prednisone (PRED) decreases the incidence of acute rejection episodes when compared with azathioprine (AZA) or placebo (1–3). In those patients receiving 3 g/d of MMF, the highest dose used in the studies, there was a trend towards an increased incidence of cytomegaloviral sepsis (CMV). We postulated therefore that MMF may represent an independent risk factor for the development of CMV infection in patients receiving renal allografts and MMF at our institution. Having altered the triple drug regime from CSA, AZA (2‐2.5 mg/kg/d) and PRED to CSA. MMF (2 g/d) and PRED in July 1995, we elected to study all patients undergoing kidney transplantation for the 33‐month period January 1994‐September 1996, by undertaking a case control analysis to determine independent risk factors for the development of CMV infection, as defined by CMV viremia or tissue‐invasive CMV. Three CMV disease‐free control patients were matched to each case, these patients having been randomly selected from the entire pool of patients in the observation period. There were 31 CMV case patients and 102 control patients. Univariate analysis indicated that gender, a concomitant pancreas transplant, acute rejection and CMV seropositivity in the donor were risk factors. However, multivariate analysis indicated that only acute rejection and donor CMV seropositivity were independently linked (p<0.05) to CMV disease in this sample. Specifically, the odds ratio (OR) for CMV disease between MMF and AZA was 1.0 (95% confidence interval (CI): 0.46‐2.18). Therefore, in this case control study we find no evidence that MMF at a dose of 2 g/d is an independent risk factor for primary CMV viremia or tissue invasion in renal allograft recipients.
Cigarette Smoking and Observed Growth of Unruptured Intracranial Aneurysms: A Systematic Literature Review and Meta-Analysis
Pachón-Londoño, María José , Ghoche, Maged T. , Nguyen, Brandon , Maroufi, Seyed Farzad , Olson, Vita A. , Patra, Devi P. , Turcotte, Evelyn L. , Halpin, Brooke S. , Krishna, Chandan , Turkmani, Ali , Meyer, Fredric B. , Nguyen, Brandon A , Olson, Vita, Halpin, Brooke S , Bendok, Bernard R , Wang, Zhen , Bendok, Bernard R.

Mayo Clinic

Stroke | September 24, 2024 | Volume: 55 | Issue: 10 | Pages: 2420-2430

10.1161/strokeaha.124.047539 | PMID 39315827 Get It

BACKGROUND: Smoking and observed growth of intracranial aneurysms are known risk factors for rupture. The mechanism by which smoking increases this risk is not completely elucidated. Furthermore, an association between smoking and aneurysm growth has not been clearly defined in the literature. We hypothesize that smoking is associated with aneurysm growth, which, in turn, may serve as one of the mechanisms by which smoking drives rupture risk. METHODS: We report a systematic review of the literature in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. Using the R software, we performed a meta-analysis to investigate the association between smoking and the growth of unruptured intracranial aneurysms. Studies on familial aneurysms and genetic syndromes known to increase the risk of aneurysms were excluded. RESULTS: Eighteen observational studies were included with a total of 3535 patients and 4289 aneurysms with a mean follow-up period ranging from 17 to 226 months. The mean age among the studies ranged from 38.4 to 73.9 years; 74% of patients were female. Ever-smoking status (odds ratio, 1.10 [95% CI, 0.87–1.38]) and current smoking status (odds ratio, 1.43 [95% CI, 0.84–2.43]) did not show a statistically significant association with growth of intracranial aneurysms. Patients currently smoking did not have a statistically significant association with the growth of intracranial aneurysms (odds ratio, 1.18 [95% CI, 0.72–1.93]) compared with patients without a smoking history. No significant association was found in patients who previously smoked compared with patients who never smoked (odds ratio, 1.46 [95% CI, 0.88–2.43]). CONCLUSIONS: Smoking is not clearly associated with the growth of unruptured intracranial aneurysms, despite trends being observed, there is no statistical association. The mechanism by which smoking increases rupture risk might not be growth. In patients for whom observation is recommended, the absence of growth over time in the setting of smoking history does not, therefore, imply protection from rupture.
Efficacy of Mindfulness-Based Stress Reduction for Breast Cancer (MBSR(BC)) a Treatment for Cancer-related Cognitive Impairment (CRCI): A Randomized Controlled Trial
Reich, Richard R. , Rodriguez, Carmen S., Nguyen, Anh , Meng, Hongdao , Tinsley, Sara , Hueluer, Gizem, Donovan, Kristine A. , Bornstein, Elizabeth, Nidamanur, Sreenidhi, Padgett, Lynne, Lucas, Jean M., Fonseca, Tamela , Joshi, Anisha, Lin, Katherine, Goodman, Matthew , Hülür, Gizem , Tinsley, Sara , Hueluer, Gizem , Lengacher, Cecile A. , Park, Jong Y. , Moscoso, Manolete S. , Kiluk, John V. , Kip, Kevin E.

Mayo Clinic

Journal of Integrative and Complementary Medicine | September 18, 2024 | Volume: 31 | Issue: 1 | Pages: 75-91

10.1089/jicm.2024.0184 | PMID 39291332 Get It

Introduction: The Mindfulness-Based Stress Reduction (MBSR) Program for breast cancer survivors (BCS) is designed to enhance cognitive training through formal and informal meditational practices. This randomized clinical trial (RCT) aimed to evaluate if BCS assigned to either the MBSR(BC), Breast Cancer Education Support (BCES), or Usual Care (UC) regimens experienced greater improvements at 6, 12, and 26 weeks on objective and subjective cognitive performance. Methods: BCS ( n = 212) randomized to a three-group RCT: MBSR(BC) ( n = 91), BCES ( n = 90), or UC ( n = 31) were assessed on cognitive performance and symptoms at baseline, 6, 12, and 26 weeks. Linear mixed models were fit to evaluate the effects of the MBSR(BC) program, hypothesizing ordered effect improvements: (MBSR[BC] highest, BCES intermediate, UC lowest) along with baseline characteristics evaluated as moderators. Results: Of the BCS (mean age of 57), 73% were White, and non-Hispanic, and 77% received both chemotherapy (CT) and radiation. Cognitive performance improved in all groups. Although there were no statistically significant between-group differences in cognitive outcomes, significant symptom reductions occurred for the MBSR(BC) group ( p = 0.003). Within-group effect size analysis at 26 weeks showed substantial improvements in all three groups (effect sizes >0.50) in subjective impairments and quality of life (effect size >0.50) and objective measures of cognitive performance. MBSR(BC) showed the largest within-group effect size in the reduction of fatigue (effect size = 0.81). Effect sizes occurred in the hypothesized direction for 10 of the 18 outcomes. Discussion: Although the MBSR(BC) program did not show significant differences in cognitive performance compared with BCES and UC, all groups improved and reductions in fatigue were beneficial for MBSR(BC). Results suggest that cognitive performance may improve after CT over time considering one’s natural history. Furthermore, BCS enrolled in RCTs may be more motivated to improve their health status (NCT02786797).
Predictive value of follow-up infarct volume on functional outcomes in middle cerebral artery M2 segment vessel occlusion stroke treated with mechanical thrombectomy
Yedavalli, Vivek, Salim, Hamza , Musmar, Basel , Adeeb, Nimer , Naamani, Kareem El, Henninger, Nils , Sundararajan, Sri Hari , Kühn, Anna Luisa, Khalife, Jane, Ghozy, Sherief, Tan, Benjamin Yong‐Qiang , Regenhardt, Robert W. , Heit, Jeremy J , Rouchaud, Aymeric, Sheth, Sunil, Puri, Ajit S., Dyzmann, Christian , Colasurdo, Marco, Barreau, Xavier, Renieri, Leonardo, Filipe, João Pedro , Harker, Pablo, Abdalkader, Mohamad , Marotta, Thomas R. , Spears, Julian , Biswas, Arundhati , Clarençon, Frédéric , Varela, Ricardo , Baker, Amanda , Essibayi, Muhammed Amir , Altschul, David , Gonzalez, Nestor R. , Möhlenbruch, Markus , Costalat, Vincent, Gory, Benjamin, Stracke, Christian Paul , Hecker, Constantin, Shaikh, Hamza, Liebeskind, David S. , Alexandre, Andrea , Tancredi, Illario, Faizy, Tobias D. , Kalsoum, Erwah , Lubicz, Boris , Patel, Aman B. , Guenego, Adrien, Investigators, for the MAD MT, Heit, Jeremy J. , Yedavalli, Vivek , Colasurdo, Marco , Salim, Hamza , Scarcia, Luca , Regenhardt, Robert W , Fiehler, Jens , Alexandru Radu, Răzvan , Klein, Piers , Ota, Takahiro , Jabbour, Pascal , Nguyen, Thanh N , Essibayi, Muhammed Amir , Gonzalez, Nestor R , Möhlenbruch, Markus A , Liebeskind, David S. , Alexandre, Andrea M , Heit, Jeremy J , Altschul, David J , Musmar, Basel , Yedavalli, Vivek S , Colasurdo, Marco , Henninger, Nils , Tan, Benjamin Yq , Varela, Ricardo , Naamani, Kareem El , Kühn, Anna Luisa , Khalife, Jane , Ghozy, Sherief , Cancelliere, Nicole M , Bernstock, Joshua D. , Rouchaud, Aymeric , Fiehler, Jens , Sheth, Sunil A , Puri, Ajit S , Barreau, Xavier , Renieri, Leonardo , Harker, Pablo , Radu, Răzvan Alexandru , Klein, Piers , Mowla, Ashkan , Jabbour, Pascal , Siegler, James E. , Nguyen, Thanh N. , Costalat, Vincent , Gory, Benjamin , Aziz‐Sultan, Mohammad Ali , Hecker, Constantin , Pedicelli, Alessandro , Tancredi, Illario , Mendes Pereira, Vitor , Guenego, Adrien , Dmytriw, Adam A. , Investigators, for the MAD MT

Mayo Clinic

European Stroke Journal | September 14, 2024 | Volume: 10 | Issue: 2 | Pages: 431-441

10.1177/23969873241275531 | PMID 39269154 Get It

Abstract Background: Medium vessel occlusion (MeVO) strokes, particularly affecting the M2 segment of the middle cerebral artery, represent a critical proportion of acute ischemic strokes, posing significant challenges in management and outcome prediction. The efficacy of mechanical thrombectomy (MT) in MeVO stroke may warrant reliable predictors of functional outcomes. This study aimed to investigate the prognostic value of follow-up infarct volume (FIV) for predicting 90-day functional outcomes in MeVO stroke patients undergoing MT. Methods: This multicenter, retrospective cohort study analyzed data from the Multicenter Analysis of primary Distal medium vessel occlusions: effect of Mechanical Thrombectomy (MAD-MT) registry, covering patients with acute ischemic stroke due to M2 segment occlusion treated with MT. We examined the relationship between 90-day functional outcomes, measured by the modified Rankin Scale (mRS), and follow-up infarct volume (FIV), assessed through CT or MRI within 12–36 h post-MT. Results: Among 130 participants, specific FIV thresholds were identified with high specificity and sensitivity for predicting outcomes. A FIV ⩽5 ml was highly specific for predicting favorable and excellent outcomes. The optimal cut-off for both prognostications was identified at ⩽15 ml by the Youden Index, with significant reductions in the likelihood of favorable outcomes observed above a 40 ml threshold. Receiver Operator Curve (ROC) analyses confirmed FIV as a superior predictor of functional outcomes compared to traditional recanalization scores, such as final modified thrombolysis in cerebral infarction score (mTICI). Multivariable analysis further highlighted the inverse relationship between FIV and positive functional outcomes. Conclusions: FIV within 36 h post-MT serves as a potent predictor of 90-day functional outcomes in patients with M2 segment MeVO strokes. Establishing FIV thresholds may aid in the prognostication of stroke outcomes, suggesting a role for FIV in guiding post intervention treatment decisions and informing clinical practice. Future research should focus on validating these findings across diverse patient populations and exploring the integration of FIV measurements with other clinical and imaging markers to enhance outcome prediction accuracy.
An Ultrathin Coating of Microcapsules Enhances the Function of Encapsulated Hepatocyte Spheroids
Lee, Seonhwa , Nguyen, Kianna M. , Gonzalez‐Suarez, Alan M. , Revzin, Alexander , Choi, Daheui , Revzin, Alexander , Gonzalez-Suarez, Alan M , Nguyen, Kianna M , Gwon, Kihak , Hoyos‐Vega, José M. de , Stybayeva, Gulnaz

Mayo Clinic

ACS Applied Materials & Interfaces | September 13, 2024 | Volume: 16 | Issue: 38 | Pages: 51411-51420

10.1021/acsami.4c08329 | PMID 39269915 Get It

WATER versus WATER II 5‐year update: Comparing Aquablation therapy for benign prostatic hyperplasia in 30–80‐cm3 and 80–150‐cm3 prostates
Berjaoui, Mohamad Baker , Nguyen, David‐Dan , Almousa, Saud, Daher, Karim , Barber, Neil , Bidair, Mo, Gilling, Peter , Anderson, Paul , Zorn, Kevin C. , Badlani, Gopal , Humphreys, Mitch, Kaplan, Steven A. , Kaufman, Ronald P., Elterman, Dean , Desai, Mihir , Roehrborn, Claus, Bhojani, Naeem , Bidair, Mohamed

Mayo Clinic

BJUI Compass | September 10, 2024 | Volume: 5 | Issue: 11 | Pages: 1137-1147

10.1002/bco2.430 | PMID 39539565 Get It

AbstractObjectiveThis study aims to compare the long‐term outcomes of Aquablation for small‐to‐moderate (30–80 cm3) prostates with the outcomes for large (80–150 cm3) prostates at 5‐year follow up.MethodsThe Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER; NCT02505919) is a prospective, double‐blind, international clinical trial encompassing 116 patients, examining Aquablation versus transurethral resection of the prostate (TURP) for LUTS/BPH in prostates sized between 30 and 80 cm3. In parallel, WATER II (W‐II; NCT03123250), a prospective, multicentre, single‐arm international clinical trial, explores Aquablation outcomes in prostates ranging from 80 to 150 cm3. Baseline parameters and 60‐month outcomes were scrutinized using statistical analyses, including Students' t test, Wilcoxon tests for continuous variables, and Fisher's test for binary variables.ResultsThere is a significant improvement in International Prostate Symptom Score (IPSS) from baseline to 60 months in both WATER (22.9 to 7.0) and WATER II (23.2 to 6.8) (P = 0.852). Urinary flow rate (Qmax) increased in both groups from baseline to 60 months (WATER: 9.4 to 17.3 cc/s; WATER II: 8.7 to 17.1 cc/s) (P = 0.933). Immediate and sustained enhancements were observed in IPSS and Qmax. At 5 years, a notable percentage of patients in both groups were BPH medication‐free (WATER: 99%; WATER II: 94%) (P = 0.0517) and free from surgical retreatment (WATER: 95%; WATER II: 97%) (P = 0.508).ConclusionsThe 5‐year follow‐up affirms that Aquablation therapy exhibits sustained outcomes, minimal irreversible complications, and low retreatment rates for treating LUTS/BPH, irrespective of prostate volume ranging from 30 to 150 cm3.
American Foregut Society Cooperative White Paper on Mechanisms of Pathologic Reflux and Antireflux Surgery
Nguyen, Ninh T. , Dayyeh, Barham Abu, Chang, Kenneth J. , Lipham, John C. , Bell, Reginald , Dunst, Christy M. , Mittal, Ravinder K., Oelschlager, Brant K. , Hinojosa, Marcelo W. , Brunaldi, Vitor , Buckley, Francis Paul, Thosani, Nirav C , Yadlapati, Rena , Kahrilas, Peter J.

Mayo Clinic

Foregut: The Journal of the American Foregut Society | September 6, 2024 | Volume: 5 | Issue: 1 | Pages: 16-26

10.1177/26345161241276454 Get It

Background: Within the spectrum of gastroesophageal reflux disease (GERD), pathologic reflux applies to the subset of patients with either erosive esophagitis or abnormal esophageal acid exposure on pH-metry, consequences of a dysfunctional antireflux barrier (ARB). Methods: The American Foregut Society (AFS) tasked a 13-member working group of expert foregut surgeons and esophagologists (The ARB Cooperative) to develop a white paper on ARB function, dysfunction, and mechanisms of action of antireflux surgery through discussion of relevant literature summarized herein. Results: The ARB Cooperative concluded that pathologic reflux is a consequence of the interplay between progressive anatomical distortion of the ARB and physiology. Factors contributing to ARB dysfunction include (1) separation of crural diaphragm from the lower esophageal sphincter with widening of the hiatus and diminished crural diaphragm sphincteric function; (2) loss of the intra-abdominal lower esophageal sphincter segment with complete disabling of the flap valve component of the ARB; (3) axial hiatal hernia leading to reflux during swallow-induced lower esophageal sphincter (LES) relaxation, LES hypotension, inspiration related reflux, a lowered threshold for eliciting transient LES relaxations, and increased compliance of the gastroesophageal junction leading to greater diameter of sphincter opening during transient LES relaxations. With regard to antireflux surgery, the objectives include: (1) reduction of hiatal hernia and restoration of the intra-abdominal esophageal segment; (2) repair of the dilated hiatus; (3) restoring flap valve function by modifying gastroesophageal anatomy; and (4) restricting gastroesophageal junction opening during periods of relaxation. Conclusions: This ARB Cooperative white paper supports the concept of there being 3 major inter-related mechanisms promoting ARB competence: the LES as an intrinsic sphincter, the crural diaphragm as an extrinsic sphincter, and the gastroesophageal valve, a mechanical 1-way valve. Pathological reflux occurs with progressive anatomical disruption of the ARB which in turn leads to physiological dysfunction, the severity of which parallels the extent of anatomical disruption. The corollary of this is that the primary mechanism of antireflux surgery is to restore the ARB by eliminating or compensating for its anatomical disruption. It is the hope of the cooperative that understanding the proposed framework will help clinicians and researchers in improving antireflux procedures.
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study
Jhaveri, Komal , Lim, Elgene , Jeselsohn, Rinath , Cynthia, X. , Hamilton, Erika , Osborne, Cynthia R. , Bhave, Manali Ajay, Kaufman, Peter A. , Beck, J. Thaddeus , Manso, Luís , Parajuli, Ritesh , Wang, Hwei-Chung, Tao, Jessica J. , Harnden, Kathleen , Yonemori, Kan , Dhakal, Ajay , Neven, Patrick , Aftimos, Philippe , Pierga, Jean‐Yves , Lu, Yen‐Shen , Larson, Timothy , Jerez, Yolanda , Sohn, Joohyuk , Saura, Cristina , Bardia, Aditya , Sammons, Sarah , Bacchion, Francesca , Li, Yujia , Estrem, Shawn T. , Nguyen, Bastien , Ismail‐Khan, Roohi , Smyth, Lillian M. , Beeram, Muralidhar , Jhaveri, Komal L , Ma, Cynthia , Hamilton, Erika P , Manso Sanchez, Luis , Im, Seock-Ah , Harnden, Kathleen , Yonemori, Kan , Dhakal, Ajay , Neven, Patrick , Aftimos, Philippe , Pierga, Jean-Yves , Lu, Yen-Shen , Larson, Timothy , Sideras, Kostandinos , Sohn, Joohyuk , Kim, Sung-Bae , Saura, Cristina , Bardia, Aditya , Sammons, Sarah L , Li, Yujia , Nguyen, Bastien , Ismail-Khan, Roohi , Smyth, Lillian , Beck, Joseph T , Im, Seock‐Ah , Sideras, Kostandinos , Yuen, Eunice , Rodrik-Outmezguine, Vanessa S.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2024 | Volume: 42 | Issue: 35 | Pages: 4173-4186

10.1200/jco.23.02733 | PMID 39241211 Get It

PURPOSE Imlunestrant is a next-generation oral selective estrogen receptor (ER) degrader designed to deliver continuous ER target inhibition, including in ESR1- mutant breast cancer. This phase Ia/b trial determined the recommended phase II dose (RP2D), safety, pharmacokinetics, and efficacy of imlunestrant, as monotherapy and in combination with targeted therapy, in ER-positive (ER+) advanced breast cancer (ABC) and endometrial endometrioid cancer. The ER+/human epidermal growth factor receptor 2–negative (HER2–) ABC experience is reported here. METHODS An i3+3 dose-escalation design was used, followed by dose expansions of imlunestrant as monotherapy or in combination with abemaciclib with or without aromatase inhibitor (AI), everolimus, or alpelisib. Imlunestrant was administered orally once daily and with the combination partner per label. RESULTS Overall, 262 patients with ER+/HER2– ABC were treated (phase Ia, n = 74; phase Ib, n = 188). Among patients who received imlunestrant monotherapy (n = 114), no dose-limiting toxicities or discontinuations occurred. At the RP2D (400 mg once daily), patients (n = 51) reported grade 1-2 nausea (39.2%), fatigue (39.2%), and diarrhea (29.4%). Patients at RP2D had received previous cyclin-dependent kinase 4/6 inhibitor (CDK4/6i; 92.2%), fulvestrant (41.2%), and chemotherapy (29.4%) for ABC and achieved a median progression-free survival (mPFS) of 7.2 months (95% CI, 3.7 to 8.3). Among patients who received imlunestrant + abemaciclib (n = 42) and imlunestrant + abemaciclib + AI (n = 43), most (69.4%) were treatment-naïve for ABC; all were CDK4/6i-naïve. Patients treated with imlunestrant + everolimus (n = 42)/alpelisib (n = 21) had received previous CDK4/6i (100%), fulvestrant (34.9%), and chemotherapy (17.5%) for ABC. No new safety signals or interactions with partnered drugs were observed. The mPFS was 19.2 months (95% CI, 13.8 to not available) for imlunestrant + abemaciclib and was not reached for imlunestrant + abemaciclib + AI. The mPFS with imlunestrant + everolimus/alpelisib was 15.9 months (95% CI, 11.3 to 19.1)/9.2 months (95% CI, 3.7 to 11.1). Antitumor activity was evident regardless of ESR1 mutation status. CONCLUSION Imlunestrant, as monotherapy or in combination with targeted therapy, had a manageable safety profile with evidence of preliminary antitumor activity in ER+/HER2– ABC.
Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Streiff, Michael B. , Holmstrom, Bjorn, Angelini, Dana E. , Ashrani, Aneel A. , Diep, Robert , Fogerty, Annemarie E., Gallastegui, Nicolas , Gangaraju, Radhika , Rojas‐Hernandez, Cristhiam M. , Goldhaber, Samuel Z. , Kubal, Timothy, Leavitt, Andrew D., Mann, Janelle , Mantha, Simon , Morton, Colleen , Nester, Alex, O’Brien, Andrew , Ranade, M. , Salmasi, Amirali , Schaefer, Jordan K. , Williams, Eliot C., Wun, Theodore, Nguyen, Jamie , Freedman-Cass, Deborah A., Sliker, Bailee , Ashrani, Aneel, Schaefer, Jordan K , Buckner, Tyler W. , Fertrin, Kleber Yotsumoto , Ibrahim, Ibrahim , Leavitt, Andrew D. , Lim, Ming Y , Mann, Janelle, O’Brien, Andrew, Ortel, Thomas L. , Pine, Alexander B. , Pishko, Allyson M. , Wool, Geoffrey D. , Montgomery, Sarah E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 5, 2024 | Volume: 22 | Issue: 7 | Pages: 483-506

10.6004/jnccn.2024.0046 | PMID 39236759 Get It

The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease provide strategies for the prevention, diagnosis, and treatment of venous thromboembolism (VTE) in adult patients with cancer. VTE is a common and life-threatening condition in patients with cancer, and its management often requires multidisciplinary efforts. The NCCN panel is comprised of specialists spanning various fields, including cardiology, hematology, medical oncology, internal medicine, interventional radiology, and pharmacology. The content featured in this issue specifically addresses the evaluation and recommended treatment options outlined in the NCCN Guidelines for the diverse subtypes of cancer-associated VTE.